Physician
Odell, Robert
Odell, Robert was paid $130K by Medicaid between Jan 2018 and Nov 2020, across 14 billing codes. Its largest line is J3300, Injection, triamcinolone acetonide, preservative free, 1 mg — 40% of everything it billed.
33Billing provider infoODELL, ROBERT
LAS VEGAS, NV 89117
LAS VEGAS, NV 89117
33aNPI1013957026assigned 06/07/2006
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$130K
24GClaims2,827
24DCodes billed14
24AFirst – last monthJan 2018 – Nov 2020
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Nevada
Rank by total paid#11 of 21
Median peer was paid$130K
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,559 | $60K | |
| 2019 | 839 | $51K | |
| 2020 | 429 | $19K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 40% | 382 | 212 | $53K |
| 97032 | 21% | 930 | 193 | $28K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 336 | 320 | $22K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.6% | 187 | 157 | $9K |
| 64635 | 5.7% | 57 | 30 | $7K | |
| 64483 | 3.2% | 37 | 35 | $4K | |
| 64636 | 1.8% | 55 | 17 | $2K | |
| 64493 | 1.6% | 25 | 24 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 74 | 69 | $1K |
| 82962 | <1% | 348 | 280 | $411.47 | |
| 64494 | <1% | 12 | 12 | $396.16 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 17 | 16 | $368.97 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.